LLY · 10-Q · 2026Q3 · Full report
Medicare GLP-1 Bridge Program
ELI LILLY & Co · 2026-10-29 · Importance 34 · Surprise 42 · In source text
Under the Medicare GLP-1 Bridge program, Medicare beneficiaries gained access to discounted Lilly obesity medicines from July 1, 2026 through December 31, 2027. Individual state Medicaid programs may separately choose to expand access. Lilly is engaging with CMS on longer-term Medicare access, but uptake and the effects of the arrangements remain uncertain and could affect pricing, demand, access, and revenue.
Key facts
- Under the Medicare GLP-1 Bridge program, Medicare beneficiaries obtained access to discounted Lilly obesity medicines effective July 1, 2026 through December 31, 2027. source
- Individual state Medicaid programs have the option to expand access to Lilly obesity medicines under the Medicare GLP-1 Bridge program. source
- Lilly continues to engage with CMS on long-term Medicare access to obesity medicines, but continued uptake from expanded access is unknown. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Under the Medicare GLP-1 Bridge program, Medicare beneficiaries obtained access to discounted Lilly obesity medicines effective July 1,… |